NOX4 and Related Biomarkers in ADPKD

Description

To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).

Conditions

Autosomal Dominant Polycystic Kidney Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).

NOX4, Mitochondria and Related Biomarkers in Autosomal Dominant Polycystic Kidney Disease

NOX4 and Related Biomarkers in ADPKD

Condition
Autosomal Dominant Polycystic Kidney Disease
Intervention / Treatment

-

Contacts and Locations

Rochester

Mayo Clinic, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * ADPKD (based on Ravine et al. criteria)
  • * Class 1 A-E according to imaging classification
  • * Male and female subjects 15 - 40 years of age
  • * Estimated GFR\> 70 mL/min/1.73 m2 (CKD-EPI)
  • * Ability to provide written, informed consent
  • * Class 2 according to imaging classification
  • * Concomitant systemic disease affecting the kidney
  • * Diabetes mellitus
  • * Predicted urine protein excretion in \>1 g/24 hrs
  • * Use of antioxidants i.e. vitamins, Nrf2 activators
  • * Abnormal urinalysis

Ages Eligible for Study

15 Years to 40 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Maria V Irazabal, M.D., Ph.D., PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2025-12